Evidence map›Paper›PMID 26526034›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2016

CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.

David A Loeffler, Lynnae M Smith, Mary P Coffey, Jan O Aasly, Peter A LeWitt

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

David A LoefflerNeurology Research Laboratory, Department of Neurology, Beaumont Hospital-Royal Oak, Beaumont Health, 3601 West Thirteen Mile Road, Royal Oak, MI, 48073, USA. DLoeffler@beaumont.edu.
Lynnae M SmithNeurology Research Laboratory, Department of Neurology, Beaumont Hospital-Royal Oak, Beaumont Health, 3601 West Thirteen Mile Road, Royal Oak, MI, 48073, USA.
Mary P CoffeyDepartment of Biostatistics, Beaumont Hospital-Royal Oak, Beaumont Health, Royal Oak, MI, USA.
Jan O AaslyDepartment of Neurology, St. Olav's Hospital, Trondheim, Norway.
Peter A LeWittDepartment of Neurology, Henry Ford West Bloomfield Hospital, West Bloomfield, MI, USA.
Beaumont Hospital, Royal Oak · USSt Olav's University Hospital · NOWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leucine-rich repeat kinase 2 (LRRK2) gene mutations are the most common genetic cause of Parkinson's disease (PD). CSF specimens from LRRK2 + PD patients and healthy LRRK2 mutation carriers are, therefore, useful for biomarker studies. This study examined the hypothesis that differences are present between subjects with sporadic PD (sPD), PD carriers of LRRK2 mutations (LRRK2 + PD), healthy control subjects lacking LRRK2 mutations (CTL), and LRRK2 mutation-carrying healthy controls (LRRK2 + CTL) for CSF concentrations of six potential PD biomarkers. Two of these proteins, nuclear factor (erythroid-derived 2)-like 2 ("Nrf2") and heat shock 70 kDa protein 8 ("HSPA8"), were detected in preliminary ELISAs, then measured in a larger cohort (60 sPD, 10 LRRK2 + PD, 23 CTL, 31 LRRK2 + CTL). No statistically significant differences were found between the groups (Nrf2 p = 0.13, HSPA8 p = 0.21). Nrf2 concentrations in LRRK2 + PD subjects were strongly positively associated with Unified Parkinson's Disease Rating Scale (UPDRS) total and motor scores [Spearman rho = 0.77 (p = 0.012) and 0.83 (p = 0.005)] and negatively associated with Montreal Cognitive Assessment (MoCA) scores (rho = -0.57; p = 0.11). Partial correlation coefficient calculations indicated that disease duration contributed to the associations of Nrf2 levels with UPDRS scores and with MoCA scores in this group. While CSF Nrf2 and HSPA8 do not appear to offer diagnostic biomarkers for PD, the associations between Nrf2 levels and UPDRS scores in LRRK2 + PD patients merit further investigation.

Indexed as

AgedBiomarkersEnzyme-Linked Immunosorbent AssayFemaleGenetic Predisposition to DiseaseHeterozygoteHSC70 Heat-Shock ProteinsHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MaleMiddle AgedMutationNF-E2-Related Factor 2Parkinson DiseaseBiomarkersHSC70 Heat-Shock ProteinsHSPA8 protein, humanLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanNFE2L2 protein, humanNF-E2-Related Factor 2BiomarkersCerebrospinal fluidHSPA8LRRK2Nrf2Parkinson’s disease

Identifiers

PMID26526034
OpenAlexW1922725943

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.